FDA approves gene test for post-natal detection of mental problems in children

A novel blood test that detects intellectual disabilities in babies has now gotten a nod from The Food and Drug Administration.

In an announcement made Friday, the agency said that it has authorized marketing of the Affymetrix CytoScan Dx Assay. The test uses a blood sample from the child to analyze his/her genome and detect chromosomal changes that could be associated with mental difficulties.

Certain intellectual disabilities such as Down syndrome and DiGeorge syndrome are linked with chromosomal variations. According to the National Institutes of Health and the American Academy of Pediatrics, about two to three percent of all American children have some kind of developmental delays.

Read the full, original story: FDA Okays Blood Test that Detects Chromosomal Changes Linked with Intellectual Disabilities in Children

Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: How dangerous COVID mutant strains develop

Infographic: How dangerous COVID mutant strains develop

Sometime in 2019, probably in China, SARS CoV-2 figured out a way to interact with a specific "spike" on the ...

Philip Njemanze: Leading African anti-GMO activist claims Gates Foundation destroying Nigeria

Nigerian anti-GMO activist, physician, and inventor pushes anti-gay and anti-GMO ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend